Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Celebrating Rare Disease Day and 40 Years of the Orphan Drug Act Advocating for Rare Disease Patients and Their Families


News provided by

IndoUSrare

Feb 08, 2023, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Figure: A collage of selected art4rare submissions from 2021 and 2022
Figure: A collage of selected art4rare submissions from 2021 and 2022

February is Rare Disease Month. It has been 40 years since the groundbreaking Orphan Drug Act of 1983, which encourages the pharmaceutical industry with incentives to pursue research and development of orphan drugs for patients living with rare diseases. Dr. Harsha Rajasimha, the Founder & Executive Chairman of IndoUSrare, is trailblazing a path toward community engagement and global advocacy for rare disease patients and their families.

HERNDON, Va., Feb. 8, 2023 /PRNewswire-PRWeb/ -- Global life expectancy has more than doubled over the last two centuries, from less than 30 years to more than 72 years.(1) Despite the advances during the 'golden age of medicine' throughout the first half of the 20th century, for persons living with rare diseases, 26% still die before the age of five, and depending on the severity of the disease, 37% have a reduced life expectancy.(2) Pharmaceutical companies were historically loathe to research and develop life-saving drugs and treatments for rare diseases because it wasn't profitable marketing drugs to such a small segment of the population. Rare disease patients became known as 'orphans,' having been abandoned by prescription drug manufacturers.(3) In 1983, the U.S. Congress passed the Orphan Drug Act to incentivize drug manufacturers to pursue the development of drug treatments for rare diseases. Dr. Harsha Rajasimha is the Founder and Executive Chairman of the Indo-US Organization for Rare Diseases (IndoUSrare), a not-for-profit organization that seeks to bridge the gap between the western and eastern hemispheres when it comes to orphan diseases. He notes, "It has been 40 years since this watershed moment in the research and development of treatments for rare diseases. While we celebrate our significant progress, we must continue to look toward the still foggy road ahead."

The FDA's Orphan Drug Act describes a rare disease as a medical condition that affects less than 200,000 people in the United States. There are currently over 10,000 rare diseases that impact more than 30 million people nationwide. For 40 years, the FDA has worked with patients, patient advocates, and researchers, encouraging the development of safe and effective drugs, biologics, and treatment products for orphan diseases.(4) When the FDA grants an orphan drug designation, sponsors and developers can receive research grants, tax credits for clinical trials, and a potential seven years of market exclusivity. To the latter, Congress determined the benefits of increased access to new treatments for rare disease patients, countervail granting drug sponsors a monopoly of an approved orphan drug.(5)

Our vision is to accelerate research and development of diagnostics and therapeutics through education, advocacy, training, research, digital patient engagement, new technology platforms for registries, clinical trials, and investments

Post this

The U.S. Department of Health and Human Services (DHHS) reports that the passage of the Orphan Drug Act has 'unquestionably stimulated' the development of orphan drugs.(5) From 1983 to 2019, the FDA conferred 5,099 drugs and biologics orphan drug designation. The top three orphan drug designations include oncology (1,910 | 37%), neurology (674 | 13%), and infectious diseases (436 | 9%). The proportion of designations for pediatric-onset diseases has increased to 27% from 2010 to 2020.(6) Clinical trials have become more patient-centric by incorporating electronic patient-reported outcomes, patient advocacy groups, and nonprofit organizations dedicated to driving policy and advancements in the treatment of rare disease patients.

Frank Sasinowski, MS, MPH, JD, Director at Hyman Phelps McNamara P.C., and Founding board member of IndoUSrare says, "One in 10 persons in every community around the globe are afflicted by 1 of the 10,000 rare diseases that exist. Forty years ago, almost no one was trying to develop treatments for any rare disease. Now there are over 1,080 orphan therapies for over 500 rare diseases. Progress is being made all over the world as people with rare diseases come together to share their medical stories in registries that accelerate the development of new therapies."

"For all of this progress," Dr. Rajasimha observes, "approximately 93% of orphan diseases remain without any FDA-approved drugs. In countries such as India, the Drug Controller General of India (DCGI) may waive the need for additional clinical trials for already FDA-approved orphan drugs. At present, there are more than 1,200 active clinical trials recruiting patients for gene therapies; five cell/gene therapies have been approved by the FDA so far, and this number is expected to grow tenfold over the next decade, which means we could see hundreds and even thousands of genetic diseases having new treatments in our lifetime."

IndoUSrare focuses on accelerating therapies for rare diseases by building collaborative bridges between the U.S. and the Indian subcontinent for education, advocacy, and research. Dr. Rajasimha adds, "Our vision is to accelerate research and development of diagnostics and therapeutics through education, advocacy, training, research, digital patient engagement, new technology platforms for registries, clinical trials, and investments."

February is Rare Disease Month, and February 28, 2023, is International Rare Disease Day. Its mission is to raise awareness and bring about change for over 300 million people living with rare diseases across the globe, as well as their families and caregivers. Rare Disease Day features special talks by key opinion leaders, panel discussions, and lived experience accounts from patients living with rare diseases worldwide. Started in 2008, Rare Disease Day is patient-led and includes contributions from individuals, families, caregivers, healthcare professionals, researchers, clinicians, policymakers, and industry representatives.

Dr. Rajasimha explains, "Rare Disease Month gives patients and their families a voice. Too many may never see or benefit from future breakthroughs in treatment for their own condition in their lifetime. Their advocacy is pure and full of compassion for the millions who are suffering worldwide. The orphan disease R&D community also has an ideal opportunity during Rare Disease Month to share their progress, amplify their message, and urge continued progress globally. We need rare disease advocacy and registries to become global villages with a reach beyond the United States and Europe to Asia, Africa, and Latin America. South Asia, including the Indian subcontinent, is densely populated, with a quarter of the world's population living there. It's critical for those in the rare disease community dedicated to advancing education, research, encouraging policy enhancements, and improving treatments and quality of life for those living with a rare disease to come together and make themselves heard."

IndoUSrare will be hosting a fireside chat with a legend this Rare Disease Day and distributing awards for the ongoing Art4Rare and Science4Rare contests that will conclude on Feb 21, 2023.

About IndoUSrare
IndoUSrare is a humanitarian nonprofit 501(c)(3) tax-exempt public charity organization based in the United States. Founder and Chairman Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than 10 years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the United States to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org.

References: 
1. Roser, M., Ortiz-Ospina, E., & Ritchie, H. (2013). Life Expectancy. Our World in Data. ourworldindata.org/life-expectancy#:~:text=Globally%20the%20life%20expectancy%20increased
2. Rare Diseases & Critical Care. (n.d.). Home. aop-health.com/global_en/rare-diseases#:~:text=Many%20rare%20diseases%20are%20life%2Dthreatening%20or%20very%20burdensome&text=About%2026%25%20of%20the%20patients
3. Research, C. for D. E. and. (2019). Orphan Products: Hope for People With Rare Diseases. FDA. fda.gov/drugs/information-consumers-and-patients-drugs/orphan-products-hope-people-rare-diseases
4. Commissioner, O. of the. (2020, February 20). Rare Diseases at FDA. FDA. fda.gov/patients/rare-diseases-fda
5. OFFICE OF INSPECTOR GENERAL THE ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT. (2001). oig.hhs.gov/oei/reports/oei-09-00-00380.pdf
6. Miller, K. L., Fermaglich, L. J., & Maynard, J. (2021). Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet Journal of Rare Diseases, 16. doi.org/10.1186/s13023-021-01901-6

Media Contact

Karla Jo Helms, JOTO PR™, 727-777-4619, [email protected]

Twitter

SOURCE IndoUSrare

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.